JAK2 Antibody

Product Specifications

Background

JAK2 is a member of the JAK family of kinases that also include JAK1, JAK3, and TYK2 (1,2) . JAK kinases are activated following tyrosine phosphorylation of cytokine receptors after ligand binding. JAK2 activation promotes the recruitment and phosphorylation of STAT3 and STAT5. These transcription factors then translocate to the nucleus where they bind specific DNA promoter sequences resulting in the transcription of genes that regulate cell proliferation, differentiation, and apoptosis (3) . Mice with a disrupted JAK2 gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis (4) .

NCBI Gene ID

3717

Swiss Prot

O60674

Accession Number

NP_004963

Host

Rabbit

Reactivity

Human, Mouse, Rat

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Stem Cell, Apoptosis

Purification

JAK2 antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1212 - 3T3 Cell Lysate

Concentration

1 mg/mL

Homology

Predicted species reactivity based on immunogen sequence: Pig: (100%), Chicken: (82%)

Buffer

JAK2 antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

JAK2 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

Fragment

IgG

Specificity

JAK2 antibody is human, mouse and rat reactive. JAK2 antibody is predicted to not cross-react with other members of the JAK family of proteins.

Symbol

JAK2

NCBI Official Name

Janus kinase 2

NCBI Organism

Homo sapiens

Background Reference 01

Wilks AF, Harpur AG, Kurban RR, et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell Biol. 1991; 11:2057-66.

Background Reference 02

Quintas-Cardama A and Verstovsek S. Molecular pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin. Can. Res. 2013; 19:1933-40.

Background Reference 03

Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 2007; 7:673-83.

Background Reference 04

Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93:397-409.